Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial.

Autor: Davar D; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Department of Computational and Systems Biology, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: davard@upmc.edu., Morrison RM; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Department of Computational and Systems Biology, University of Pittsburgh, Pittsburgh, PA, USA., Dzutsev AK; Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Karunamurthy A; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Department of Dermatology, University of Pittsburgh, Pittsburgh, PA, USA., Chauvin JM; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Amatore F; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA., Deutsch JS; Division of Dermatopathology, Johns Hopkins University, Baltimore, MD, USA., Das Neves RX; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA., Rodrigues RR; Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA; Genetics and Microbiome Core, Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., McCulloch JA; Genetics and Microbiome Core, Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Wang H; Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA., Hartman DJ; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA., Badger JH; Genetics and Microbiome Core, Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Fernandes MR; Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Bai Y; Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA; Department of Human Genetics, University of Pittsburgh, Pittsburgh, PA, USA., Sun J; Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA; Department of Human Genetics, University of Pittsburgh, Pittsburgh, PA, USA., Cole AM; Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Aggarwal P; Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Fang JR; Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Deitrick C; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Bao R; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA., Duvvuri U; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA, USA., Sridharan SS; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA, USA., Kim SW; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA, USA., A Choudry H; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Division of Surgical Oncology, Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA., Holtzman MP; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Division of Surgical Oncology, Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA., Pingpank JF; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Division of Surgical Oncology, Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA., O'Toole JP; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Division of Plastic Surgery, Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA., DeBlasio R; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Jin Y; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Ding Q; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Gao W; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Groetsch C; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Pagliano O; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Rose A; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Urban C; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Singh J; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA., Divarkar P; Nanostring Technologies, Seattle, WA, USA., Mauro D; Checkmate Pharmaceuticals, Cambridge, MA, USA., Bobilev D; Checkmate Pharmaceuticals, Cambridge, MA, USA., Wooldridge J; Checkmate Pharmaceuticals, Cambridge, MA, USA., Krieg AM; Checkmate Pharmaceuticals, Cambridge, MA, USA., Fury MG; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA., Whiteaker JR; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Zhao L; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Paulovich AG; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Najjar YG; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA., Luke JJ; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA., Kirkwood JM; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA., Taube JM; Division of Dermatopathology, Johns Hopkins University, Baltimore, MD, USA; Tumor Microenvironment Core, Bloomberg-Kimmel Institute of Immunotherapy, Mark Foundation Center for Advanced Imaging and Genomics, Johns Hopkins University, Baltimore, MD, USA., Park HJ; Department of Dermatology, University of Pittsburgh, Pittsburgh, PA, USA; Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA., Trinchieri G; Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA. Electronic address: trinchig@mail.nih.gov., Zarour HM; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Department of Dermatology, University of Pittsburgh, Pittsburgh, PA, USA; Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: zarourhm@upmc.edu.

Publikováno v: Cancer cell [Cancer Cell] 2024 Nov 11; Vol. 42 (11), pp. 1898-1918.e12. Date of Electronic Publication: 2024 Oct 31.

Electronic texture of the thermoelectric oxide Na0.75CoO2

Autor: Julien, M. -H., de Vaulx, C., Mayaffre, H., Berthier, C., Horvatic, M., Simonet, V., Wooldridge, J., Balakrishnan, G., Lees, M. R., Chen, D. P., Lin, C. T., Lejay, P.

Publikováno v: Phys. Rev. Lett. 100, 096405 (2008)

From 59Co and 23Na NMR, we demonstrate the impact of the Na+ vacancy ordering on the cobalt electronic states in Na0.75CoO2: at long time scales, there is neither a disproportionation into 75 % Co3+ and 25 % Co4+ states, nor a mixed-valence metal wit

Externí odkaz: http://arxiv.org/abs/0801.4095

Intraplanar Magnetic Excitations in Na0.5CoO2: An Inelastic Neutron Study

Autor: Wooldridge, J., Balakrishnan, G., Paul, D. McK., Frost, C., Bourges, P., Lees, M. R.

Inelastic neutron scattering measurements mapping the in-plane magnetic interactions of Na0.5CoO2 reveal dispersive excitations at points above an energy gap Eg = 11.5(5) meV at the superstructural Bragg reflections. The excitations are highly damped

Externí odkaz: http://arxiv.org/abs/cond-mat/0608196

The magnetic field and pressure dependence of the magnetic ordering transition in NaxCoO2 (0.6

Autor: Wooldridge, J., Paul, D. McK., Balakrishnan, G., Lees, M. R.

Publikováno v: J. Phys.: Condens. Matter 18 (2006) 4731-4739

We have measured the magnetic field (H<90 kOe) and pressure (P<10 kbar) dependence of the magnetic ordering temperature, Tmag, in single crystal samples of NaxCoO2 for a range of Na concentrations (0.60